DDInter624 DDInter1744
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Tamoxifen
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Tamoxifen
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatic steatosis
Hepatic steatosis {u} (Side Effect) is caused by {v} (Compound) Tamoxifen
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Diphenhydramine
Diphenhydramine {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Efavirenz {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Dextropropoxyphene
Dextropropoxyphene {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Orphenadrine
Orphenadrine {u} (Compound) resembles {v} (Compound) Tamoxifen
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Clomifene
Clomifene {u} (Compound) resembles {v} (Compound) Tamoxifen
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is regulated by {v} (Gene) KIAA0196
KIAA0196 {u} (Gene) is upregulated by {v} (Compound) Tamoxifen
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatic steatosis
Hepatic steatosis {u} (Side Effect) is caused by {v} (Compound) Dextropropoxyphene
Dextropropoxyphene {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Efavirenz {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Blood creatinine increased {u} (Side Effect) is caused by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tamoxifen
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tamoxifen (Compound)
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Tamoxifen (Compound)
Efavirenz (Compound) causes Hepatic steatosis (Side Effect) and Hepatic steatosis (Side Effect) is caused by Tamoxifen (Compound)
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Diphenhydramine (Compound) and Diphenhydramine may lead to a major life threatening interaction when taken with Tamoxifen
Efavirenz (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dextropropoxyphene (Compound) and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Orphenadrine (Compound) and Orphenadrine (Compound) resembles Tamoxifen (Compound)
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Clomifene (Compound) and Clomifene (Compound) resembles Tamoxifen (Compound)
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is regulated by KIAA0196 (Gene) and KIAA0196 (Gene) is upregulated by Tamoxifen (Compound)
Efavirenz (Compound) causes Hepatic steatosis (Side Effect) and Hepatic steatosis (Side Effect) is caused by Dextropropoxyphene (Compound) and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Efavirenz (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Tamoxifen